Your author says "Rae, who is a breast cancer researcher himself, agrees it remains a valuable system for studying metastases." Wouldn't it be better to choose a more appropriate cell line from now on, rather than a mistaken cell line, to study metastases, specifically for breast cancer, now that it seems clear that there has been a mix-up somewhere nearly 25 years ago? Also, various comments following this article show that the last word has not be spoken on this 'mistaken identity.' I don't know whether aromatase inhibitors or other compounds that are used to treat metastatic breast cancers have ever been used to treat metastatic melanoma even in animal models. It would certainly be interesting to find out what happens. There must be some commonalities between various metastatic cancers, although the primary tumors may have different origins.